rezpegaldesleukin
rezpegaldesleukin: developed by 1 company · 4 clinical trials tracked.
rezpegaldesleukin evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could rezpegaldesleukin → NKTR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| NEKTAR THERAPEUTICS (NKTR) Moderate to Severe Atopic Dermatitis; Moderate-to-Severe Ato… | Phase 2 |
Clinical Trials (4)
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis
Primary endpoint: US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Primary endpoint: US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Primary endpoint: Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)
Primary endpoint: Mean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16
Frequently asked questions
Who is developing rezpegaldesleukin?
rezpegaldesleukin is being developed by NEKTAR THERAPEUTICS.
How many clinical trials involve rezpegaldesleukin?
BioSniper tracks 4 clinical trials involving rezpegaldesleukin.